FindTrial
Sign In

Risk factors for Mucormycosis following COVID-19

Risk Factors of Post-COVID-19 Rhino-Orbito-Cerebral Mucormycosis in India: Case-control study, 2021

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034743
Enrollment
836
Registered
2021-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B461- Rhinocerebral mucormycosis

Interventions

None listed

Sponsors

Dr P Manickam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Are lab confirmed ROCM patients diagnosed after 1st April 2021, Treated in/discharged from the study hospital for ROCM, Had COVID-19 prior to the diagnosis of ROCM, Hospitalised for COVID-19 care in the study hospital or elsewhere

Exclusion criteria

Exclusion criteria: Dead, Not traceable (phone number not available/ wrong number/ no response)

Design outcomes

Primary

MeasureTime frame
Proportion of participants with uncontrolled diabetes mellitus during COVID-19 management Timepoint: At baseline—

Secondary

MeasureTime frame
Proportion of participants with steroid use during COVID-19 management Timepoint: At Baseline—

Countries

India

Contacts

Public ContactDr P Manickam

ICMR-National Institute of Epidemiology

manickam@nie.gov.in04426136415

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026